Skip to main content
BCDA
NASDAQ Life Sciences

BioCardia Receives Nasdaq Minimum Bid Price Deficiency Notice

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.01
Mkt Cap
$15.29M
52W Low
$0.75
52W High
$2.29
52W Position info
35% above low
Off High info
56% below high
Rel. Volume
Market data snapshot near publication time

BCDA sits 35% above its 52-week low of $0.75.

Summary

BioCardia received a Nasdaq minimum bid price deficiency notice, giving it until February 16, 2027, to regain compliance. The stock has traded below $1.00 for 30 consecutive business days.


Key Events · Legal and Risk Events · BCDA

  • Nasdaq Deficiency Notice

    On August 19, 2026, BioCardia received a notice that its stock traded below $1.00 for 30 consecutive business days, violating Nasdaq's minimum bid price rule.

  • Compliance Deadline

    The company has 180 calendar days, until February 16, 2027, to regain compliance by closing at or above $1.00 for ten consecutive business days.

  • Delisting Risk

    If compliance is not regained, BioCardia may be eligible for a second 180-day period, but would likely need to effect a reverse stock split to qualify.

  • Prior Extension Superseded

    This new notice supersedes the Nasdaq extension granted on June 12, 2026, which had a compliance deadline of October 7, 2026.


Analysis · BCDA · Life Sciences

A new Nasdaq deficiency notice landed on August 19, 2026, after BioCardia's stock traded below $1.00 for 30 consecutive business days. The company now has until February 16, 2027, to regain compliance by trading at or above $1.00 for ten consecutive business days. This supersedes the prior extension granted in June 2026 and puts delisting risk back in focus. The company may pursue a reverse stock split if needed, but no assurance is given.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BCDA was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $0.75 to $2.29. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BCDA - Latest Insights

BCDA
Nov 12, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.831
Real-time Price: $0.7801 info
Change: -$0.0509 (-6%) info
Market Cap: $12.58M info
BCDA
Oct 07, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.7801 info
Change: -$0.316 (-29%) info
Market Cap: $12.58M info
BCDA
Aug 24, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.980
Real-time Price: $0.7801 info
Change: -$0.1999 (-20%) info
Market Cap: $12.58M info
BCDA
Aug 12, 2026, 4:27 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.902
Real-time Price: $0.7801 info
Change: -$0.1219 (-14%) info
Market Cap: $12.58M info
BCDA
Aug 12, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.870
Real-time Price: $0.7801 info
Change: -$0.0899 (-10%) info
Market Cap: $12.58M info